{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:47:28Z","timestamp":1758476848438},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40261-016-0431-x","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T06:32:34Z","timestamp":1468305154000},"page":"819-827","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Results of ACES (Antihypertensive Combinations\u2019 Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies"],"prefix":"10.1007","volume":"36","author":[{"given":"Zolt\u00e1n","family":"N\u00e1dh\u00e1zi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba Andr\u00e1s","family":"D\u00e9zsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"431_CR1","unstructured":"National Institute for Health and Clinical Excellence. Clinical guideline 127: hypertension. Clinical management of primary hypertension in adults. http:\/\/www.nice.org.uk\/guidance\/CG127\/NICEGuidance . Accessed 2 Jul 2016."},{"key":"431_CR2","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121\u201358.","journal-title":"J Hypertens"},{"issue":"1","key":"431_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","volume":"32","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3\u201315.","journal-title":"J Hypertens"},{"key":"431_CR4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11883-011-0214-z","volume":"14","author":"R Deano","year":"2012","unstructured":"Deano R, Sorrentino M. Lipid effects of antihypertensive medications. Curr Atheroscler Rep. 2012;14:70\u20137.","journal-title":"Curr Atheroscler Rep."},{"key":"431_CR5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high risk patients. N Engl J Med. 2008;359:2417\u201328.","journal-title":"N Engl J Med"},{"key":"431_CR6","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.2337\/dc06-1373","volume":"29","author":"G Bakris","year":"2006","unstructured":"Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"431_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1559-4572.2008.07819.x","volume":"3","author":"G Bakris","year":"2008","unstructured":"Bakris G, Molitch M, Zhou Q, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET Study. J Cardiometab Syndr. 2008;3(1):18\u201325.","journal-title":"J Cardiometab Syndr"},{"key":"431_CR8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895\u2013906.","journal-title":"Lancet"},{"key":"431_CR9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2337\/dc07-1768","volume":"31","author":"KA Gupta","year":"2008","unstructured":"Gupta KA, Dahl\u00f6f B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008;31:982\u20138.","journal-title":"Diabetes Care"},{"key":"431_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/157340207779815473","volume":"3","author":"M Burnier","year":"2007","unstructured":"Burnier M, Bullani R, Vogt B, et al. Beta-blockers for the treatment of essential hypertension: what are the arguments against their use as first line therapy? Curr Hypertension Rev. 2007;3:15\u201320.","journal-title":"Curr Hypertension Rev."},{"key":"431_CR11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-126-12-199706150-00004","volume":"126","author":"D Giugliano","year":"1997","unstructured":"Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med. 1997;126:955\u20139.","journal-title":"Ann Intern Med"},{"issue":"3","key":"431_CR12","first-page":"466","volume":"16","author":"K Uchida","year":"1994","unstructured":"Uchida K, Azukizawa S, Kigoshi T, et al. Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance. Clin Ther. 1994;16(3):466\u201370.","journal-title":"Clin Ther"},{"key":"431_CR13","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.1996.03530440029033","volume":"275","author":"RH Grimm","year":"1996","unstructured":"Grimm RH, Flack JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension: Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA. 1996;275:1549\u201356.","journal-title":"JAMA"},{"key":"431_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40256-015-0116-5","volume":"15","author":"S Taddei","year":"2015","unstructured":"Taddei S. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Am J Cardiovasc Drugs. 2015;15:185\u201394.","journal-title":"Am J Cardiovasc Drugs."},{"key":"431_CR15","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, et al. (CAMELOT): effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA. 2004;292:2217\u201326.","journal-title":"JAMA"},{"issue":"Suppl 3","key":"431_CR16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF00877863","volume":"9","author":"TF L\u00fcscher","year":"1995","unstructured":"L\u00fcscher TF, Wenzel RR, Moreau P, Takase H. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther. 1995;9(Suppl 3):509\u201323.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl. 2","key":"431_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200059002-00004","volume":"59","author":"G Leonetti","year":"2000","unstructured":"Leonetti G. Clinical positioning of indapamide sustained release 1.5\u00a0mg in management protocols for hypertension. Drugs. 2000;59(Suppl. 2):27\u201338.","journal-title":"Drugs."},{"issue":"15","key":"431_CR18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2165\/00002018-200124150-00006","volume":"24","author":"P Weidmann","year":"2001","unstructured":"Weidmann P. Metabolic profil of indapamide sustained-release in patients with hypertension. Drug Saf. 2001;24(15):1155\u201365.","journal-title":"Drug Saf"},{"key":"431_CR19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1472-8206.2005.00377.x","volume":"19","author":"J Sassard","year":"2005","unstructured":"Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundam Clin Pharmacol. 2005;19:637\u201345.","journal-title":"Fundam Clin Pharmacol"},{"key":"431_CR20","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/eurheartj\/ehp103","volume":"30","author":"JJ Brugts","year":"2009","unstructured":"Brugts JJ, Ninomiy T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009;30:1385\u201394.","journal-title":"Eur Heart J"},{"issue":"10","key":"431_CR21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","volume":"11","author":"S Jacob","year":"1998","unstructured":"Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens. 1998;11(10):1258\u201365.","journal-title":"Am J Hypertens"},{"key":"431_CR22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1527-3466.2001.tb00061.x","volume":"19","author":"J Cheng","year":"2001","unstructured":"Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev. 2001;19:152\u201371.","journal-title":"Cardiovasc Drug Rev"},{"key":"431_CR23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1527-5299.2002.00718.x","volume":"8","author":"WM Book","year":"2002","unstructured":"Book WM. Carvedilol: a nonselective \u03b2-blocking agent with antioxidant properties. Congest Heart Fail. 2002;8:173\u20137.","journal-title":"Congest Heart Fail."},{"key":"431_CR24","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","volume":"292","author":"LG Bakris","year":"2004","unstructured":"Bakris LG, Fonseca V, Katholi RE, et al. (GEMINI): metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292:2227\u201336.","journal-title":"JAMA"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0431-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:15:27Z","timestamp":1498313727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0431-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0431-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]}}}